<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513643</url>
  </required_header>
  <id_info>
    <org_study_id>ISPS_Dose-ranging</org_study_id>
    <nct_id>NCT00513643</nct_id>
  </id_info>
  <brief_title>Metabolic Effect of Insulin Aspart and Human Insulin in Different Doses</brief_title>
  <official_title>Pharmacodynamic and Pharmacokinetic Properties of Insulin Aspart: Dose - Ranging vs. Human Soluble Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Profil Institut für Stoffwechselforschung GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Profil Institut für Stoffwechselforschung GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The metabolic effect of three different doses of insulin aspart and human insulin are
      investigated with the euglycaemic glucose clamp technique.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double-blind, randomized, 6-period cross-over study in 16 healthy subjects. Each patient
      participates in 6 euglycemic glucose clamp experiments each.

      The time interval between the study days is 2 to 28 days. At the clamp visits, subjects are
      connected to a Biostator (MTB Medizintechnik, Ulm, Germany) and receive an intravenous human
      insulin infusion (rate of 0.15 mU/kg/min) over the duration of each experiment to prevent a
      rise in endogenous insulin secretion. After a baseline period of 2 h the trial drug (6, 12,
      or 24 U of either Insulin Aspart or regular human insulin in random order) are administered
      s.c. with a syringe into the abdominal wall. Glucose infusion rates (GIR) necessary to keep
      blood glucose concentrations close to the clamp level of 90 mg/dl (5 mmol/l) are administered
      and recorded by the Biostator every minute for a period of 12 h post-dosing. Blood samples
      are drawn at regular intervals for the analysis of C-peptide and (depending on the trial drug
      administered) serum insulin or serum Insulin Aspart concentrations (measured with specific
      ELISAs).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">June 2002</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC GIR 360-720 min</measure>
    <time_frame>at each dosing (6 times during the trial)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK endpoints such as C max/ins, t max/ins, AUC ins 0-120 min, AUC ins 360-720 min, AUC ins 0-720 min</measure>
    <time_frame>at each dosing visit (6 times during the study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD endpoints like GIR max, t max/GIR, AUC GIR 0-120 min, AUC GIR 0-720 min, t &gt;2/GIR, early and late t 50%/GIR</measure>
    <time_frame>at each dosing visit (6 times during the study)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 U insulin aspart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 U insulin aspart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 U insulin aspart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 IU human regular insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 IU human regular insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 IU human regular insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin aspart</intervention_name>
    <description>6, 12, 24 U s.c.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Novorapid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human regular insulin</intervention_name>
    <description>6, 12 and 24 IU sc</description>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <other_name>Actrapid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Signed informed consent obtained before any trial-related activities

          -  Healthy subjects between 18 and 45 years inclusive

          -  Considered generally healthy upon completion of medical history and physical
             examination

          -  Body mass index (BMI) &lt; 27 kg/m2

          -  HbA1c &lt; 6,1 %

          -  Non-smoker for at least three months

          -  Females of childbearing potential using acceptable methods of contraception, including
             tubal ligation, an intrauterine device (IUD), the oral contraceptive pill or barrier
             methods.

        Exclusion Criteria:

          -  Participation in any other clinical trial and receipt of any investigational drug
             within four weeks prior to this trial

          -  Previous participation in this trial

          -  Clinically significant abnormal haematology or biochemistry screening test

          -  Any disease requiring use of non topical prescription medicines

          -  Any serious systemic infectious disease that occurred in the four weeks prior to the
             first dose of test drug

          -  Any intercurrent illness that may affect blood glucose

          -  Current addiction to alcohol or substances of abuse as determined by the investigator

          -  Known or suspected allergy against insulin or any component of the composition of the
             trial drug

          -  Blood donation &gt; 500 ml within the last nine weeks

          -  Mental incapacity, unwillingness or language barriers precluding adequate
             understanding or co-operation

          -  If female, subject is pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Heise, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut für Stoffwechselforschung GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.profil-research.de</url>
    <description>Profil Institut für Stoffwechselforschung</description>
  </link>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2007</study_first_submitted>
  <study_first_submitted_qc>August 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2007</study_first_posted>
  <last_update_submitted>August 8, 2007</last_update_submitted>
  <last_update_submitted_qc>August 8, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2007</last_update_posted>
  <keyword>euglycaemic glucose clamp</keyword>
  <keyword>duration of action</keyword>
  <keyword>late metabolic activity</keyword>
  <keyword>hypoglycaemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

